Team

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nullam vitae tortor ut leo mollis semper nec a nisi. Fusce convallis id enim a placerat. Proin ultricies tempus semper. Sed at eleifend lectus, placerat mattis velit. Integer in mauris eget nibh cursus efficitur. Cras egestas ut ipsum eu rutrum. Vestibulum in eros eu mi porta interdum. Aliquam et mi venenatis, imperdiet orci vel, tincidunt purus. Proin posuere ultrices lorem, vel cursus massa finibus sed. Sed eleifend massa eu nisi fringilla, id semper turpis aliquam. Nunc blandit venenatis arcu eget pretium. Interdum et malesuada fames ac ante ipsum primis in faucibus. Vestibulum pretium eu neque a posuere. Pellentesque pharetra ex eget diam dapibus ultricies bibendum non felis.

Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia curae; Suspendisse in magna molestie orci maximus finibus. Aliquam accumsan enim vitae massa porta, sed blandit tortor lacinia. Fusce ornare venenatis arcu, a dictum libero tincidunt sit amet. Aliquam vitae sollicitudin lectus. Maecenas non tellus quis ante luctus vestibulum. Nullam ipsum purus, mattis nec cursus nec, porta nec dolor.

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Cras mattis eget arcu at ornare. Pellentesque justo odio, posuere a euismod vel, euismod eget libero. Morbi volutpat mi nec massa iaculis eleifend. Nunc volutpat, orci vitae dictum aliquet, justo ante vehicula nunc, vel semper felis ipsum non felis. Morbi posuere venenatis lectus, vel aliquam neque porttitor in. In id ligula quis risus sodales convallis.

Alfred Reszka, PhD joined Lifescience Dynamics in 2019 as Chief Business Officer. Al came with over 22 years of experience at Merck & Co., Inc., most recently serving 12 years in their Global Competitive Intelligence department. Al played a pivotal role in building and developing a world-class global competitive intelligence group with high impact on brand and corporate strategy. As an executive manager of large CI teams, Al has seen, been involved in and led hundreds of secondary and primary CI research projects, competitive simulations and strategic formulation projects. Al was also co-chair for the Pharma CI conference in the US and EU from 2017 to 2019.

Previously, Al was Executive Director and Head of Strategic Business Intelligence at Merck & Co. based in its US corporate headquarters. In this role, Al oversaw a broad portfolio of intelligence service offerings covering several therapeutic areas, corporate strategy, mergers and acquisitions, business development and licensing. In this capacity, he guided the drafting of the basic research strategy for Immuno-Oncology and support of Keytruda, contributed to the commercial launch and counter-launch strategies for brands and Merck’s Biosimilars business, and was one of few selected to inform the drafting of Merck’s 2025 corporate strategy. During his tenure, Al also led several of Merck & Co.’s special strategy projects that were successful in identifying targets for acquisitions and partnering.

Al earned his B.S. and M.S. in Microbiology and his PhD in Cell and Structural Biology at the University of Illinois, Urbana-Champaign. His research included papillomaviruses (M.S.) and cell adhesion through the integrin receptors (Ph.D.). He conducted postdoctoral research at the University of Washington, Seattle, with a focus on the interaction between the Mitogen-Activated Protein Kinases (ERKs 1 and 2) and the microtubule cytoskeleton. His earlier research as part of the Merck Research Laboratories focused on the elucidation of the mechanism of action of the nitrogen-containing bisphosphonates with a focus on alendronate, which is the active pharmaceutical ingredient of Fosamax.

Alfred is based in our Manhattan, NYC, East Coast office.

Peter Kelly, PhD joined Lifescience Dynamics in 2019 as an Engagement Manager. Peter brings diverse experience from finance, business, strategy, relationship and project management and scientific training to help his clients achieve success.

Prior to joining Lifescience Dynamics, Peter worked in financial services at the Bank of England. At the Bank, Peter led teams responsible for the supervision of several large and complex financial services companies, including the insurance firm AIG and investment bank Deutsche Bank. As a senior manager, he evaluated the business models and balance sheets of financial services firms, analysed and scrutinised whether management was appropriately identifying and managing risks to its business, and then created and implemented proactive solutions. This required in-depth understanding of banking and insurance product profiles, corporate strategy, competitive landscape, financial metrics, forecasting models, systems of risk management and governance, capital and liquidity. He also represented the Bank at international conferences and worked in partnership with EU and US regulatory agencies. During his time at the Bank, he was recognised as a subject matter expert in several areas, including financial risk modelling and effective governance of international financial groups.

Before working at the Bank of England, Peter worked as Senior Researcher for the UK Medical Research Council’s Clinical Sciences Centre, where he was part of the Nitric Oxide Signalling Group in the lab of Professor James M. Leiper, PhD.

Peter earned his B.A. in Molecular and Cellular Biology at the University of California at Berkeley, and later completed a PhD in Biochemistry from University College London School of Medicine. His thesis research focused on the role of endogenous nitric oxide synthase inhibitors in the modulation of immune and cardiovascular signalling. Peter also worked at the bench in research labs at Stanford University Medical School, the Memorial Sloan-Kettering Cancer Center and Imperial College London. His works are published in a wide range of peer-reviewed scientific journals.

Peter is based in our San Francisco, West Coast office.